218 related articles for article (PubMed ID: 28711324)
1. Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung.
Hirai A; Yoneda K; Shimajiri S; Kuroda K; Hanagiri T; Fujino Y; Tanaka F
J Thorac Cardiovasc Surg; 2018 Jan; 155(1):382-392.e1. PubMed ID: 28711324
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
6. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
[TBL] [Abstract][Full Text] [Related]
7. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
8. Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung.
Han YB; Kwon HJ; Park SY; Kim ES; Kim H; Chung JH
J Pathol Transl Med; 2019 Mar; 53(2):86-93. PubMed ID: 30636390
[TBL] [Abstract][Full Text] [Related]
9. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
[TBL] [Abstract][Full Text] [Related]
11. ASO Author Reflections: Clinical Implications of Programmed Death-Ligand 2 (PD-L2) Expression as an Independent Prognostic Marker in Lung Adenocarcinoma: Different Characteristics of PD-L2-Positive Patients from Those with Programmed Death-Ligand 1.
Takamori S; Takada K; Maehara Y
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):668-669. PubMed ID: 31368016
[No Abstract] [Full Text] [Related]
12. Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma.
Inamura K; Yokouchi Y; Sakakibara R; Kobayashi M; Subat S; Ninomiya H; Nagano H; Nomura K; Okumura S; Ishikawa Y
Jpn J Clin Oncol; 2016 Oct; 46(10):935-941. PubMed ID: 27511990
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.
Serra P; Petat A; Maury JM; Thivolet-Bejui F; Chalabreysse L; Barritault M; Ebran N; Milano G; Girard N; Brevet M
Lung Cancer; 2018 Apr; 118():62-68. PubMed ID: 29572005
[TBL] [Abstract][Full Text] [Related]
14. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
[TBL] [Abstract][Full Text] [Related]
16. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
17. A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.
Toyokawa G; Takada K; Tagawa T; Hamamoto R; Yamada Y; Shimokawa M; Oda Y; Maehara Y
Ann Thorac Surg; 2019 Feb; 107(2):393-400. PubMed ID: 30343006
[TBL] [Abstract][Full Text] [Related]
18. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
19. The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
Wu S; Shi X; Sun J; Liu Y; Luo Y; Liang Z; Wang J; Zeng X
Oncotarget; 2017 Mar; 8(10):16421-16429. PubMed ID: 28145884
[TBL] [Abstract][Full Text] [Related]
20. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Zhou F; Wang X; Liu F; Meng Q; Yu Y
Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]